Roche (VTX:ROG) has been given a CHF 260 target price by equities researchers at UBS Group in a report issued on Monday, www.boersen-zeitung.de reports. The brokerage presently has a “neutral” rating on the healthcare company’s stock. UBS Group’s price target indicates a potential upside of 4.08% from the company’s current price.
A number of other brokerages have also commented on ROG. set a CHF 203 price objective on shares of Roche and gave the stock a “sell” rating in a report on Friday, October 20th. Baader Bank set a CHF 256 price objective on shares of Roche and gave the stock a “buy” rating in a report on Tuesday, November 21st. Goldman Sachs Group set a CHF 325 price objective on shares of Roche and gave the stock a “buy” rating in a report on Thursday, December 7th. Barclays set a CHF 305 price objective on shares of Roche and gave the stock a “buy” rating in a report on Wednesday, December 27th. Finally, Berenberg Bank set a CHF 260 price objective on shares of Roche and gave the stock a “neutral” rating in a report on Tuesday, October 24th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. Roche presently has an average rating of “Hold” and an average price target of CHF 263.42.
Roche (ROG) opened at CHF 249.80 on Monday. Roche has a 1-year low of CHF 226.10 and a 1-year high of CHF 273. The company has a market cap of $216,110.00 and a price-to-earnings ratio of 22.20.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2018/01/10/ubs-group-reiterates-chf-260-price-target-for-roche-rog.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.